Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study.

Rowe SM, Zuckerman JB, Dorgan D, Lascano J, McCoy K, Jain M, Schechter MS, Lommatzsch S, Indihar V, Lechtzin N, McBennett K, Callison C, Brown C, Liou TG, MacDonald KD, Nasr SZ, Bodie S, Vaughn M, Meltzer EB, Barbier AJ

Open source

DOI: 10.1016/j.jcf.2023.04.008
Published: 2023 Jul
Container: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jcf.2023.04.008,
  title = {Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study.},
  author = {Rowe SM and Zuckerman JB and Dorgan D and Lascano J and McCoy K and Jain M and Schechter MS and Lommatzsch S and Indihar V and Lechtzin N and McBennett K and Callison C and Brown C and Liou TG and MacDonald KD and Nasr SZ and Bodie S and Vaughn M and Meltzer EB and Barbier AJ},
  year = {2023},
  journal = {Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society},
  doi = {10.1016/j.jcf.2023.04.008},
  url = {https://doi.org/10.1016/j.jcf.2023.04.008}
}

RIS

TY  - JOUR
TI  - Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study.
AU  - Rowe SM
AU  - Zuckerman JB
AU  - Dorgan D
AU  - Lascano J
AU  - McCoy K
AU  - Jain M
AU  - Schechter MS
AU  - Lommatzsch S
AU  - Indihar V
AU  - Lechtzin N
AU  - McBennett K
AU  - Callison C
AU  - Brown C
AU  - Liou TG
AU  - MacDonald KD
AU  - Nasr SZ
AU  - Bodie S
AU  - Vaughn M
AU  - Meltzer EB
AU  - Barbier AJ
PY  - 2023
JO  - Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
DO  - 10.1016/j.jcf.2023.04.008
UR  - https://doi.org/10.1016/j.jcf.2023.04.008
ER  -

APA

SM, R., JB, Z., D, D., J, L., K, M., M, J., MS, S., S, L., V, I., N, L., K, M., C, C., C, B., TG, L., KD, M., SZ, N., S, B., M, V., EB, M., & AJ, B. (2023). Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study.. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. https://doi.org/10.1016/j.jcf.2023.04.008

Source records

pubmed · retrieved 2026-09-25T22:32:14.661Z